20% off purchase of 2 or more Monoclonal Antibodies* | Learn More >>
Thrombospondin-1 Antibody

Thrombospondin-1 Antibody #14778

This product is discontinued

We recommend the following alternatives

  • WB
  • IP

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Thrombospondin-1 Antibody recognizes endogenous levels of total thrombospondin-1 protein.

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser670 of human thrombospondin-1 protein. Antibodies are purified by protein A and peptide affinity chromatography.

The adhesive glycoprotein thrombospondin-1 (THBS1, TSP1) localizes to the extracellular matrix (ECM) and mediates interactions between cells and the ECM and among cells. Thrombospondin-1 is a multi-domain, glycosylated protein that interacts with a wide variety of extracellular targets, including matrix metalloproteinases (MMPs), collagens, cell receptors, growth factors, and cytokines (1). The protein structure of THBS1 includes an amino-terminal laminin G-like domain, a von Willebrand factor-binding domain, and multiple thrombospondin (TSP) repeated sequences designated as type I, type II, or type III repeats. Each thrombospondin domain interacts with a distinct type of cell surface ligands or protein targets. The amino-terminal domain interacts with aggrecan, heparin, and integrin proteins. Type I TSP repeats interact with MMPs and CD36, while carboxy-terminal repeats bind the thrombospondin receptor CD47 (1). Through these interactions, THBS1 exerts diverse effects on different signaling pathways, such as VEGF receptor/NO signaling, TGFβ signaling, and the NF-κB pathway (2-5). Thrombospondin-1 is an important regulator of many biological processes, including cell adhesion/migration, apoptosis, angiogenesis, inflammation, vascular function, and cancer development (2-5). The activity of thrombospondin-1 is mainly regulated by extracellular proteases. The metalloproteinase ADAMTS1 cleaves thrombospondin, resulting in the release of peptides with anti-angiogenic properties. Elastase and plasmin proteases degrade the THBS1 protein and down regulate its activity (6). As THBS1 is an important protein inhibitor of angiogenesis, the development of thrombospondin-based compounds and their use in therapeutic studies may provide a beneficial approach to the treatment of cancer (7,8).

  1. Resovi, A. et al. (2014) Matrix Biol 37, 83-91.
  2. Lawler, P.R. and Lawler, J. (2012) Cold Spring Harb Perspect Med 2, a006627.
  3. Lopez-Dee, Z. et al. (2011) Mediators Inflamm 2011, 296069.
  4. Roberts, D.D. et al. (2012) Matrix Biol 31, 162-9.
  5. Kazerounian, S. et al. (2008) Cell Mol Life Sci 65, 700-12.
  6. Iruela-Arispe, M.L. (2008) Curr Drug Targets 9, 863-8.
  7. Mirochnik, Y. et al. (2008) Curr Drug Targets 9, 851-62.
  8. Taraboletti, G. et al. (2010) Oncotarget 1, 662-73.
Entrez-Gene Id
Swiss-Prot Acc.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.

Upstream / Downstream


Explore pathways related to this product.